The CDK4‐cyclin D1 axis is critical for glioma genesis, tumor de t velopment, and the growth of stromal‐derived cells in the surrounding microenvironment, which sustains the spread of glioma cells.[59] Despite its good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent anaplastic oligodendroglioma and recurrent glioblastoma.[60, 61] Although none of the three drugs have entered further clinical trials, all have moved from preclinical to clinical trials, suggesting that our screening pipeline is reasonable. The gene discussed is CDK4; the disease is neoplasm.